Histamine Release During Morphine and Fentanyl Anesthesia

Carl E. Rosow, M.D., Ph.D.,* Jonathan Moss, M.D., Ph.D.,* Daniel M. Philbin, M.D.,† John J. Savarese, M.D. †

High doses of morphine produce peripheral vasodilatation and frequently significant hypotension. These effects are thought to be due, in part, to the release of histamine. One putative advantage of high-dose fentanyl anesthesia is its relatively small effect on peripheral vascular resistance. In a randomized study, the authors examined the possibility that the hemodynamic differences between morphine and fentanyl might be attributable to histamine release. Fifteen patients were studied prior to coronary artery bypass surgery. Subjects received an infusion of morphine (1 mg·kg⁻¹·min⁻¹ at 100 μg·kg⁻¹·min⁻¹ [n = 8]) or fentanyl (50 μg·kg⁻¹ at 5 μg·kg⁻¹·min⁻¹ [n = 7]). Patients in the morphine group had an average 750 per cent peak increase in plasma histamine accompanied by a significant decrease in mean arterial pressure (−27 mmHg) and systemic vascular resistance (−520 dyn·s·cm⁻⁵). The greatest decrease in systemic vascular resistance occurred in those patients with the highest levels of plasma histamine (r = 0.81). Patients in the fentanyl group had no change in plasma histamine and no decrease in arterial pressure or systemic vascular resistance. Cardiac output and heart rate were comparable between the two groups. Differences in the release of histamine account for most, if not all, of the different effects of morphine and fentanyl on the peripheral vasculature. (Key words: Anesthesia; cardiovascular. Anesthesics, intravenous: morphine; fentanyl. Blood pressure: drug effects; vascular resistance. Histamine.)

High doses of morphine and fentanyl are routinely used for intravenous anesthesia in patients with minimal circulatory reserve. It is well documented that clinically useful doses of these drugs produce little in the way of myocardial depression. In volunteers and cardiac surgical patients, morphine usually produces a transient or sustained decrease in systemic vascular resistance. In contrast, when Stanley introduced the use of fentanyl-oxygen anesthesia, he noted that even 50 μg·kg⁻¹·min⁻¹ of fentanyl produced little change in peripheral vascular tone.

Morphine is known to release histamine in humans, although until recently the evidence for this was indirect, i.e., flushing and urticaria. In a recent study from our laboratory, Philbin et al. have shown that morphine does indeed produce large increases in plasma histamine and that histamine antagonists block the accompanying vasodilatation. To our knowledge, fentanyl has not been described as producing clinically observable signs of histamine release.

The development of a sensitive radioenzymatic assay for histamine and its recent improvement now make it possible to measure the small changes in plasma histamine that are produced by alkaloids of the sort used in anesthesia. The present study was designed to compare the histamine released by high doses of morphine and fentanyl in cardiac surgical patients. At the same time, we have correlated plasma histamine with changes in several hemodynamic variables.

Methods

Fifteen patients scheduled for elective coronary artery bypass surgery were studied according to an institutionally approved protocol after giving informed consent. None had signs or symptoms of congestive heart failure, and all had ejection fractions of at least 0.50 at the time of cardiac catheterization. All patients had been receiving propafenol for at least 6 weeks, with the last dose given approximately 12 h prior to anesthesia. Premedication was mg·kg⁻¹ intramuscular morphine 0.1 mg·kg⁻¹ and scopolamine 0.4 mg.

Patients were randomly allocated to a morphine or fentanyl treatment group. After placement of radial and pulmonary artery catheters while patients were under local anesthesia, control hemodynamic values were recorded. We measured radial artery pressure (BP), pulmonary artery pressure (PA), central venous pressure (CVP), and cardiac output (CO) by thermodilution. Systemic vascular resistance (SVR) was calculated as

\[
\frac{BP - CVP}{CO} \times 80
\]

Radial arterial and mixed venous (pulmonary arterial) blood samples (5 ml) were collected for determination of plasma histamine.

Oxygen was administered by mask, and the narcotic infusion was begun via an IMED® volumetric pump. Morphine (1 mg·kg⁻¹·total dose) was administered at a rate of 100 μg·kg⁻¹·min⁻¹. Fentanyl (50 μg·kg⁻¹·total dose) was given at a rate of 5 μg·kg⁻¹·min⁻¹. The total dose of morphine and the rate of administration were those routinely used for cardiac surgical procedures at this institution. The fentanyl dose and infusion rate approximated those described by Stanley.

Metocurine 0.3 mg·kg⁻¹ was administered concomitantly over a 5-min period. Respiration was assisted, then

* Assistant Professor
† Associate Professor

Received from the Department of Anesthesia, Harvard Medical School and the Anesthesia Service, Massachusetts General Hospital, Boston, Massachusetts 02114. Accepted for publication July 21, 1981. Supported in part by a grant from Janssen Pharmaceutica. Presented in part at the Seventh World Congress of Anesthesiologists, Hamburg, Germany, September 1980.

Address reprint requests to Dr. Rosow: Department of Anesthesia, Massachusetts General Hospital, Boston, Massachusetts 02114.
Results

In agreement with our previous study of morphine-induced histamine release, there were no significant differences between arterial and mixed venous plasma histamine levels; only arterial levels are reported here. There were no significant differences in baseline plasma histamine between the morphine and fentanyl groups, and these values were all within the normal range for our laboratory. The administration of fentanyl caused virtually no change in plasma histamine at any point measured (fig. 1). The morphine group had an average 750 per cent peak increase in plasma histamine, but, as in the case of our previous studies, there was a wide range of response. This varied from no detectable increase in plasma histamine to a peak histamine level of 20 ng·ml⁻¹. The latter approaches the level previously reported in anaphylactic reactions. Plasma histamine after 0.33 mg·kg⁻¹ of morphine was not a good predictor of the response to the total dose.

In the morphine group, the peak elevation in plasma histamine corresponded very well with the maximal decrease in systemic vascular resistance (−520 ± 80 dyne·s·cm⁻²) and in mean blood pressure (−27 ± 4 mmHg) from control values (fig. 2). In contrast, the fentanyl group had no change in plasma histamine, no drop in systemic vascular resistance, and no fall in mean blood pressure. Figure 3 shows that the change in systemic vascular resistance following the administration of morphine was inversely correlated with plasma histamine (r = −0.81). This indicates that those patients with the largest increases in histamine had the greatest hemodynamic responses.

Hemodynamic data collected at 5 and 10 min following drug administration must be interpreted cautiously since seven of eight morphine patients received phenylephrine. None of the patients receiving fentanyl required pressor support.

Cardiac output rose slightly in patients given morphine (P < 0.05) and did not change significantly in those given fentanyl. Heart rate did not change significantly in either group, perhaps because of residual beta blockade.

Discussion

The classic work of Schmidt and Livingston demonstrated tachyphylaxis to the hypotensive effect of morphine in dogs. Since that study, it has generally been assumed that histamine was somehow involved in the systemic response to morphine, although direct proof was lacking. The circumstantial evidence, however, was strong: intradermal injection of morphine produced a "triple response" (redness, flare, and wheal). Intrave-
nous injection of morphine or histamine produced hypotension, flushing, itching and urticaria.

Feldberg and Paton utilized a perfused cat gastrocnemius preparation and a relatively non-specific bioassay to demonstrate histamine release by three opiate alkaloids. Schachter found that meperidine induced a dose-related release of histamine from cat skin. Johnson and Moran showed that morphine released histamine from rat peritoneal mast cells without disrupting the cells themselves, although high concentrations of morphine were required.

Unfortunately, most in vivo studies of drug-induced histamine release have been restricted to the massive effects of insect venoms and the phenylethylamine polymer 48/80. Low molecular weight basic amines, such as morphine and other anesthetic drugs, release amounts of histamine that are well below the sensitivity of unmodified biological and fluorometric assays unless relatively large blood samples are taken and elaborate steps are introduced to concentrate and separate histamine from interfering substances. Lorenz and co-workers used such a technique to measure histamine released by plasma expanders and induction agents. The enzymatic isotopic assay used in this study has a sensitivity of 100 pg·ml⁻¹ and requires as little as 50 µl plasma. Thus, it has been possible to make direct, repeated measurements of the changes in plasma histamine produced by clinically useful drugs. In a previous study we used this technique to show that d-tubocurare produces a dose-related increase in plasma histamine that correlates very well with the degree of observed hypotension. Philbin et al. have recently confirmed the early in vitro morphine studies by demonstrating that 1 mg·kg⁻¹ morphine can release significant amounts of histamine. In that study, hypotension and decreased systemic vascular resistance also correlated well with elevations in plasma histamine, and most of these hemodynamic effects were blocked by pretreatment with diphenhydramine and cimetidine. This would suggest that histamine release plays an important role in determining vasomotor tone following the administration of morphine.

Opiates may produce hypotension in other ways, however. In 1972, Lowenstein et al. studied the vascular effects of morphine on the isolated, separately perfused canine gracilis muscle. They showed that there were two mechanisms responsible for the loss in peripheral vas-
cular resistance: first, there was a local direct vasodilator effect and second, a centrally mediated loss of vasomotor tone. The second effect requires intact innervation and is potentiated when baseline sympathetic tone is high. We had no a priori reason to believe that fentanyl or any other opioid should behave differently from morphine in this regard.

The results in the present study confirm prior observations that even massive doses of fentanyl produce fewer cardiovascular effects than doses of morphine routinely used in cardiac anesthesia. Furthermore, it seems clear that in this patient population, almost all of the hemodynamic difference can be accounted for by differences in the release of histamine. Baseline systemic vascular resistance and mean arterial pressure were virtually identical in the two groups. As expected, patients given morphine became hypotensive; plasma histamine rose by 750 per cent, systemic vascular resistance dropped by 42 per cent, and the two variables were well correlated. In the fentanyl group, mean arterial pressure did not change, and there was no significant change in either plasma histamine or systemic vascular resistance.

Other factors potentially influencing the hemodynamic responses (e.g., nitrous oxide, metocurine) were constant between the two groups. Hypotension secondary to narcotic-induced bradycardia might not have been demonstrable in the face of residual beta blockade, but this too should have been consistent for both groups. The opiate doses selected have clinical relevance, although they are not equianalgesic. Fentanyl is invariably considered to be 80 to 200 times as potent an analgesic as morphine (probably closer to 200 if one is considering peak effect). Assuming a comparable potency ratio still holds in this high dose range, one would expect roughly five times more opiate effect (e.g., analgesia) after 50 \( \mu \text{g} \cdot \text{kg}^{-1} \) of fentanyl than after 1 \( \text{mg} \cdot \text{kg}^{-1} \) of morphine. There is, of course, no reason to assume that histamine release is at all related to interaction at opiate receptors. The amount of histamine released probably relates primarily to the concentration of drug achieved at mast cell membranes. It is therefore reasonable to assume that histamine release will be least with extremely potent drugs such as fentanyl since clinically useful effects occur at extremely low concentrations.

The rapid intravenous administration of morphine exposes tissues to transient, high concentrations of the drug. The hemodynamic effects may be minimized by slowing the rate of infusion (thereby decreasing histamine release), or pretreating with histamine antagonists (blocking the histamine effect at end organs). On the basis of this study, the use of fentanyl would seem to be a more direct way to avoid histamine-induced effects on the peripheral circulation.

References